Eugene Toth

Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions : role of glutamic acid

We studied the effect of local administration of nicotine on the release of monoamines in striatum, substantia nigra, cerebellum, hippocampus, cortex (frontal, cingulate), and pontine nucleus and on the release of glutamic acid in striatum of rats in vivo, using microdialysis for nicotine administration and for measuring extracellular amine and glutamic acid levels. Following nicotine administration the extracellular concentration of dopamine, increased in all regions except cerebellum; serotonin increased in cingulate and frontal cortex; and norepinephrine increased in substantia nigra, cingulate cortex, and pontine nucleus. Cotinine, the major nicotine metabolite, had no effect at similar concentrations. The cholinergic antagonists mecamylamine and atropine, the dopaminergic antagonists haloperidol and sulpiride, and the excitatory amino acid antagonist kynurenic acid all inhibited the nicotine-induced increase of extracellular dopamine in the striatum. The fact that kynurenic acid almost completely prevented the effects of nicotine, and nicotine at this concentration produced a 6-fold increase of glutamic acid release, suggests that the effect of nicotine is mainly mediated via glutamic acid release.

Antagonism of phencyclidine-induced hyperactivity by glycine in mice.

We tested the effect of glycine on phencyclidine (PCP)-induced hyperactivity in mice. Glycine antagonized the locomotor stimulating effect of PCP. Correlation was found between the degree of antagonistic effect and the size of the increase in glycine in the brain. The antagonism is not due to changes in uptake, since the elevation of glycine in plasma and brain had no effect on the cerebral uptake of PCP. This pharmacological action of glycine appears to be a central effect, but some peripheral effect can not be excluded. Since glycine is not toxic at levels needed for PCP antagonism, it could be considered for ameliorating PCP psychosis. The locomotor stimulating effect of PCP is strain dependent in mouse. Some strains are responsive, such as BALB/cBy and CXBK, and some are unresponsive, such as C57BL/6 and CXBH.

Anticonvulsant effects of some inhibitory neurotransmitter amino acids.

The anticonvulsive effects of GABA, taurine, and glycine were investigated on several chemically-induced and genetic seizure models. Intravenous injections of either GABA, taurine, or glycine provided protection against 3-mercaptopropionic acid (MPA)-induced convulsions in adult Swiss mice. GABA was partially effective against isonicotinic acid hydrazide and was without effect against bicuculline-induced convulsions bProlonged administration of glycine prevented MPA-induced convulsions but not electrically induced seizures or seizures induced by strychnine or metrazol.Intragastric glycine protected young audiogenic seizure-susceptible DBA/2 mice against all three phases of sound-induced convulsions (wild running, clonic and tonic seizure), but GABA and taurine provided little or no protection. With increase of glycine, the cerebral levels of glutamine and serine also increased, but that of glutamic acid decreased. The endogenous glutamic and glycine levels were slightly higher in the brains of the audiogenic seizure-susceptible DBA/2 mice than in that of the resistant BALB/Cy strain.

Elevation of cerebral levels of nonessential amino acids in vivo by administration of large doses

Taurine, aspartic acid, glutamic acid, glycine, and GABA were administered either intragastrically or in liquid diets to mice and rats. This resulted in a great increase in the plasma concentration of the administered amino acid, with plasma levels remaining elevated for several days.The prolonged increase in plasma levels resulted in significant increases in brain levels. Under these experimental conditions, taurine, aspartic acid, and glutamic acid were increased 30–60%; glycine and GABA 100%. During these experiments, plasma levels of taurine, aspartate, and glutamate were below brain levels; those of glycine and GABA were above.The findings show that even slowly penetrating amino acid levels can be increased in brain after parenteral administration of large doses.

Subtype-specificity of the presynaptic α2-adrenoceptors modulating hippocampal norepinephrine release in rat

In vivo brain microdialysis and high-performance liquid chromatography with electrochemical detection were used to study the effect of different selective alpha 2-antagonists on hippocampal norepinephrine (NE) release in freely moving awake rat. Systemic administration (0.5 mg/kg i.p.) of either the alpha 2AD-antagonist BRL 44408 or the alpha 2BC-antagonist ARC 239 did not significantly change the basal release of NE. At a higher dose (5 mg/kg i.p.) ARC 239 was still ineffective, whereas BRL 4408 caused a significant increase of the extracellular level of NF. Similar results were obtained from in vitro perfusion experiments. Rat hippocampal slices were loaded with [3H]NE and the electrical stimulation-evoked release of [3H]NE was determined. The alpha 2-antagonists were applied in a concentration range of 10(-8) to 10(-6) M, ARC 239 was ineffective, whereas BRL 44408 significantly increased the electrically induced release of [3H]NE. In agreement with the data of microdialysis and perfusion experiments, BRL 44408 displaced [3H]yohimbine from hippocampal and cortical membranes of rat brain with high affinity whereas ARC 239 was less effective. The pKi values of eight different alpha 2-adrenergic compounds showed a very good correlation (r = 0.98, slope = 1.11 P < 0.0001) in hippocampus and frontal cortex have the alpha 2-adrenoceptors have been characterized as alpha 2d-subtype. Our data indicate that hippocampal NE release in rat is regulated by alpha 2D-adrenoceptors, a species variation of the human alpha 2A-subtype.

NMDA receptors are not involved in the MK-801-induced increase of striatal dopamine release in rat: a microdialysis study

Brain microdialysis and high-performance liquid chromatography with electrochemical detection were utilized to study the effect of the selective non-competitive NMDA antagonist MK-801 (dizocilpine) on striatal dopamine (DA) release in the anesthetized rat. Perfusion of 100 microM and 300 microM (+/-)-MK-801 through the probe did not significantly change the basal release of DA. These results suggest that excitatory amino acids do not exert a tonic excitatory influence on striatal DA release through NMDA receptors. 1 mM and 3 mM (+/-)-MK-801 caused a significant increase (398% and 580%, respectively), while there was no change in the level of dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). To clarify the mechanism of the (+/-)-MK-801-induced increase, the differential effect of its enantiomers (the active (+)-MK-801 and the less active (-)-MK-801) was determined. There was no difference in the action of these compounds: both drugs increased the striatal DA release with the same efficacy. Our data suggest that the MK-801-induced increase of striatal DA release is not an NMDA receptor-mediated effect.

Motor effects of intracaudate injection of excitatory amino acids

In a study of the role of excitatory amino acid receptors in movement disorders, the effect of the injection of glutamate (Glu), aspartate (Asp), N-methyl-D-aspartate (NMDA), quisqualate (Qu), or kainate (K) into the rat striatum was investigated. Rats were microinjected unilaterally through chronically implanted guide cannulas and their motor behavior was recorded. After 10-25 min L-Glu produced reversible periodic choreiform movements lasting 5-10 sec and contraversive rotation lasting 1-2 min. Both episodes were repeated every 2-3 min: the duration of motor effects was 60-80 min. L-Asp had an effect similar to that of L-Glu and in addition produced barrel rolling. The L-isomers of both Glu and Asp were active and the D-isomers were inactive. NMDA, Qu, and K were more potent than Glu or Asp. Each produced effects similar to that of Glu, and in addition NMDA and K produced wet-dog-shakes and masticatory movements. The motor behavior produced by Qu was identical to that of Glu, but it lasted longer. The motor effects of L-Glu were blocked by L-glutamic acid diethyl ester (GDEE) and by a larger sedative dose of 2-amino-5-phosphonopentanoic acid (AP5), but not by haloperidol, GABA, glycine (Gly), or a smaller nonsedative dose of AP5. The results suggest that the motor effects of L-Glu were produced by activation of the Qu-type (glutamatergic) receptors, not involving the dopamine and GABA systems. However, activation of the K-type receptors by L-Glu cannot be ruled out.

Glycine potentiates the action of some anticonvulsant drugs in some seizure models

The anticonvulsant effect of either phenobarbital or dilantin was potentiated by exogenous glycine in DBA/2 audiogenic seizure mice and in 3-mercaptopropionic acid-induced seizures. In seizures caused by pentylenetetrazol, glycine potentiated the anticonvulsant effect of phenobarbital only slightly; in combination with dilantin, which was ineffective by itself, it did not have an effect. Valproic acid, in large doses, prevented 3-mercaptopropionic acid-induced seizures; glycine did not potentiate its effect. Glycine thus potentiates anticonvulsant effects, but only of some drugs and only in some of the seizure models. This suggests that the mechanism of the anticonvulsant effect of glycine is similar to that of some of the anticonvulsant drugs such as dilantin and different from others, and that this mechanism is not effective in all seizure models.

Effect of acetyl-l-carnitine on extracellular amino acid levels in vivo in rat brain regions

Acetyl-l-carnitine (ALCAR) was found to have beneficial effects in senile patients. In recent years many of its effects on the nervous system have been examined, but its mechanism(s) of action remains to be elucidated. We previously reported that it causes release of dopamine in the striatum. In the present paper we report that ALCAR, when administered at intracerebral sites via microdialysis, stimulates the release of amino acids in a concentration-dependent and regionally heterogeneous manner. The effect was strong in the striatum and cerebellum, less so in the frontal cortex, and weak in the thalamus. Seven amino acids were measured: the increase in the level of aspartate, glutamate, and taurine was substantial, and the increase in the level of glycine, serine, threonine, alanine, and glutamine in the microdialysate was minor. The stimulatory effect of ALCAR on the release of amino acids in the striatum was inhibited by the muscarinic antagonist atropine, but was not inhibited by the nicotinic antagonist mecamylamine. The effect of ALCAR on the levels of most of the amino acids tested was independent of the presence of Ca2+ in the perfused. These results indicate that ALCAR, when administered intracerebrally at fairly high concentrations, can affect the level and the release not only of such neurotransmitters as acetylcholine and dopamine, but also of amino acids. The mechanism of action of ALCAR on the release of cerebral amino acids may involve the participation of muscarinic receptors or may be mediated through the release of dopamine, but the lack of Ca2+ dependence indicates a release from the cytoplasmic amino acid pool, possibly through the effect of ALCAR on cell membrane permeability.

Acetyl-L-carnitine releases dopamine in rat corpus striatum: an in vivo microdialysis study

The effect of acetyl-L-carnitine, a compound reported to be beneficial for senile patients, on the release of dopamine (DA) from the striatum was studied by using in vivo brain dialysis in anesthetized rats coupled with HPLC-electrochemical detection. Striatal infusion of acetyl-L-carnitine increased the efflux of DA with no apparent changes in efflux of DA metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and 4-hydroxy-3-methoxyphenylacetic acid (HVA). The DA-releasing effect of acetyl-L-carnitine was concentration- and Ca(2+)-dependent, and was abolished by omega-conotoxin fraction GVIA and tetrodotoxin, inhibitors of the voltage-dependent Ca2+ and Na+ channels, respectively. Nomifensine, an inhibitor of DA reuptake did not alter the DA-releasing property of acetyl-L-carnitine. DA released from the striatum by acetyl-L-carnitine was decreased by reserpine pretreatment whereas the d-amphetamine-evoked DA outflow was not affected. In contrast to acetyl-L-carnitine, d-amphetamine reduced the extracellular concentrations of DOPAC and HVA. We conclude from the present data that acetyl-L-carnitine evokes DA release from the vesicular pools of the nigrostriatal dopaminergic neurons by a Ca(2+)-dependent, exocytotic process.